<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925417</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001</org_study_id>
    <nct_id>NCT01925417</nct_id>
  </id_info>
  <brief_title>Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea</brief_title>
  <acronym>PUNCH CD</acronym>
  <official_title>A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebiotix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rebiotix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as
      a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the
      primary symptom of recurrent Clostridium difficile infection. All eligible subjects will
      receive RBX2660.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first study of a microbiota suspension derived from intestinal microbes. The
      primary assessments for this open label, multi-center study are (i) occurrence of
      product-related adverse events and (ii) resolution of CDAD at 56 days after administration of
      RBX2660. Subjects will also be assessed for time to CDAD recurrence, quality of life changes,
      and number of hospitalizations and length of stay for recurrent CDAD. Study visits will be at
      7, 30, and 60 days after RBX2660 administration with additional follow-up at 3 and 6 months
      post treatment. Patients who have had at least two recurrences of CDAD after a primary
      episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or
      have had at least two episodes of severe CDAD resulting in hospitalization may be eligible
      for the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660</measure>
    <time_frame>56 days</time_frame>
    <description>Safety will be assessed by evaluating the incidence of serious adverse events through 56 days after the last treatment with RBX2660.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term Safety</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of serious adverse events will be assessed through 6 months after the last treatment with RBX2660.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of CDAD at 56 Days</measure>
    <time_frame>56 days</time_frame>
    <description>Number of participants who were determined to be free of CDAD at Day 56 after receiving their last dose of RBX2660.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>60 days</time_frame>
    <description>Quality of life will be assessed by comparing the subject's baseline quality of life score to his/her scores obtained at the 7-, 30- and 60-day follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Hospitalization Data</measure>
    <time_frame>6 months</time_frame>
    <description>number of ICU days was collected for subjects who received RBX2660 and who were subsequently hospitalized for recurrent CDAD treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Recurrent Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>RBX2660 (microbiota suspension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RBX2660 (microbiota suspension)</intervention_name>
    <arm_group_label>RBX2660 (microbiota suspension)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years

          -  Medical record documentation of CDAD either: a) at least two recurrences after a
             primary episode and have completed at least two rounds of standard-of-care oral
             antibiotic therapy or b) have had at least two episodes of severe CDAD resulting in
             hospitalization.

          -  Willing and able to have an enema(s).

          -  Already taking or will start a course of oral antibiotics for CDAD symptoms for 10-14
             days, including at least seven days of oral vancomycin.

          -  Willing and able to complete the required subject diary.

        Exclusion Criteria:

          -  Continued (uncontrolled) CDAD after completing a 10-14 day course of oral antibiotics.

          -  Requires antibiotic therapy for a condition other than CDAD.

          -  Previous fecal transplant prior to study enrollment.

          -  History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's
             disease, or microscopic colitis.

          -  History of irritable bowel syndrome (IBS).

          -  History of chronic diarrhea.

          -  History of celiac disease.

          -  History of cirrhosis of the liver or ascites.

          -  Disease symptoms caused by a confirmed intestinal pathogen other than Clostridium
             difficile.

          -  Has a colostomy.

          -  Intraabdominal surgery within the last 60 days.

          -  Evidence of active, severe colitis.

          -  History of short gut syndrome or motility disorders.

          -  Requires the regular use of medications that affect bowel motility (e.g.,
             metoclopramide, narcotics, loperamide).

          -  Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).

          -  Planned surgery requiring perioperative antibiotics within 6 months of study
             enrollment.

          -  Life expectancy of &lt; 12 months.

          -  Compromised immune system, e.g., HIV infection (any CD4 count); AIDS-defining
             diagnosis or CD4 &lt;200/mm3; inherited/primary immune disorders; immunodeficient or
             immunosuppressed due to a medical condition or medication; current or recent (&lt; 90
             days) treatment with chemotherapy; or current or recent (&lt; 90 days) treatment with
             immunosuppressant medications.

          -  Taking steroids (≥ 20 mg a day) or is expected to be on steroids for more than 30 days
             after enrollment.

          -  Neutropenia (white blood cell count &lt;1000 cells/µL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health and University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr VA Hospital (veterans only)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Research/USD</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.</citation>
    <PMID>23323867</PMID>
  </reference>
  <reference>
    <citation>Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002. doi: 10.1093/cid/cir632. Review.</citation>
    <PMID>22002980</PMID>
  </reference>
  <reference>
    <citation>Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol. 2012 Nov;5(6):403-20. doi: 10.1177/1756283X12453637.</citation>
    <PMID>23152734</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2015</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>C diff</keyword>
  <keyword>Microbiota Restoration Therapy</keyword>
  <keyword>MRT</keyword>
  <keyword>microbiota suspension</keyword>
  <keyword>CDI</keyword>
  <keyword>CDAD</keyword>
  <keyword>Fecal transplant</keyword>
  <keyword>Fecal Microbiota Transplant</keyword>
  <keyword>FMT</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Fecal bacteriotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was from 07/15/13 to 12/16/13 at 13 medical clinics in the United States. Recruiment was performed by trained investigators and study coordinators.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RBX2660 (Microbiota Suspension)</title>
          <description>This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RBX2660 (Microbiota Suspension)</title>
          <description>Open-label; all subjects received RBX2660</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" lower_limit="26.7" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660</title>
        <description>Safety will be assessed by evaluating the incidence of serious adverse events through 56 days after the last treatment with RBX2660.</description>
        <time_frame>56 days</time_frame>
        <population>31 subjects had evaluable data at 56 days.</population>
        <group_list>
          <group group_id="O1">
            <title>RBX2660 (Microbiota Suspension)</title>
            <description>This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660</title>
          <description>Safety will be assessed by evaluating the incidence of serious adverse events through 56 days after the last treatment with RBX2660.</description>
          <population>31 subjects had evaluable data at 56 days.</population>
          <units>number of reported SAEs through 56 days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Safety</title>
        <description>The incidence of serious adverse events will be assessed through 6 months after the last treatment with RBX2660.</description>
        <time_frame>6 months</time_frame>
        <population>31 subjects had evaluable data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>RBX2660 (Microbiota Suspension)</title>
            <description>This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Safety</title>
          <description>The incidence of serious adverse events will be assessed through 6 months after the last treatment with RBX2660.</description>
          <population>31 subjects had evaluable data at 6 months.</population>
          <units>number of reported SAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of CDAD at 56 Days</title>
        <description>Number of participants who were determined to be free of CDAD at Day 56 after receiving their last dose of RBX2660.</description>
        <time_frame>56 days</time_frame>
        <population>31 subjects had evaluable data at 56 days.</population>
        <group_list>
          <group group_id="O1">
            <title>RBX2660 (Microbiota Suspension)</title>
            <description>This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of CDAD at 56 Days</title>
          <description>Number of participants who were determined to be free of CDAD at Day 56 after receiving their last dose of RBX2660.</description>
          <population>31 subjects had evaluable data at 56 days.</population>
          <units>participants with treatment success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Quality of life will be assessed by comparing the subject's baseline quality of life score to his/her scores obtained at the 7-, 30- and 60-day follow-up visits.</description>
        <time_frame>60 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Hospitalization Data</title>
        <description>number of ICU days was collected for subjects who received RBX2660 and who were subsequently hospitalized for recurrent CDAD treatment.</description>
        <time_frame>6 months</time_frame>
        <population>31 subjects had evaluable data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>RBX2660 (Microbiota Suspension)</title>
            <description>This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Hospitalization Data</title>
          <description>number of ICU days was collected for subjects who received RBX2660 and who were subsequently hospitalized for recurrent CDAD treatment.</description>
          <population>31 subjects had evaluable data at 6 months.</population>
          <units>number of particpants' ICU days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of enrollment through the 6-month follow-up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RBX2660 (Microbiota Suspension)</title>
          <description>This was an open-label, non-randomized, non-controlled subjects. All treated subjects received RBX2660 (microbiota suspension).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Clostridium difficile Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Stab Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <description>Most were mild-moderate in severity and resolved within 7 days of receiving RBX2660.</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anorectal Discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headach</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size (n=34) limits extrapolation of results to a larger population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mary Kay Sobcinski, Director of Clinical Operations</name_or_title>
      <organization>Rebiotix</organization>
      <phone>6519644488</phone>
      <email>mksobcinski@rebiotix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

